局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习

doi:10.19438/j.cjoms.2022.04.018

中国口腔颌面外科杂志 ›› 2022, Vol. 20 ›› Issue (4): 413-416.doi: 10.19438/j.cjoms.2022.04.018

• 病例报告 • 上一篇

局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习

张益益¹, 杨玥怡¹, 琚梧桐², 钟来平²

1.上海交通大学医学院附属第九人民医院口腔医学院,上海 200011;
2.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,国家口腔医学中心, 国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2022-02-15 修回日期:2022-04-24 出版日期:2022-07-20 发布日期:2022-07-20
通讯作者: 钟来平,E-mail：zhonglaiping@163.com
作者简介:张益益（1999-）,女,本科,E-mail：nanamissx@163.com

Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review

ZHANG Yi-yi¹, YANG Yue-yi¹, JU Wu-tong², ZHONG Lai-ping²

1. College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200025;
2. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2022-02-15 Revised:2022-04-24 Online:2022-07-20 Published:2022-07-20

摘要/Abstract

摘要： 新辅助治疗是针对无远处转移恶性肿瘤患者在局部治疗前进行的全身性治疗,主要目的是减少肿瘤负荷、增加肿瘤根治机会、降低远处转移、缓解症状等。本文报道2例上海交通大学医学院附属第九人民医院进行前瞻性临床试验过程中,局部晚期口腔鳞癌患者接受卡瑞利珠单抗联合阿帕替尼的新辅助治疗方案的病例,并对新辅助治疗相关文献进行复习和讨论。

关键词: 口腔鳞癌, 新辅助治疗, 多学科诊治

Abstract: Neoadjuvant therapy is systemic therapy before local treatment in patients with non-distant metastatic malignancies, aiming to reduce tumor load and distant metastasis, increase opportunity of radical resection, and relieve symptoms, et al. In this report, we presented two patients with locally advanced oral squamous cell carcinoma, who were treated with camrelizumab and apatinib as neoadjuvant therapy in Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and reviewed and discussed the relevant literatures.

Key words: Oral squamous cell carcinoma, Neoadjuvant therapy, Multidisciplinary team

中图分类号:

R739.8

张益益, 杨玥怡, 琚梧桐, 钟来平. 局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习[J]. 中国口腔颌面外科杂志, 2022, 20(4): 413-416.

ZHANG Yi-yi, YANG Yue-yi, JU Wu-tong, ZHONG Lai-ping. Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review[J]. China J Oral Maxillofac Surg, 2022, 20(4): 413-416.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Leemans CR, Snijders PJF, Brakenhoff RH.The molecular landscape of head and neck cancer[J]. Nat Rev Cancer, 2018, 18(5): 269-282.
[3] 郭海鹏, 刘木元, 杨熙鸿, 等. 新辅助化疗对口腔癌生存率影响的Meta分析[J]. 汕头大学医学院学报, 2014, 27(02): 100-103.
Guo HP, Liu MY, Yang XH, et al.Meta analysis of survival effect in patients with oral carcinoma receiving neoadjuvant chemotherapy[J]. Journal of Shantou University Medical College, 2014, 27(2): 100-103.
[4] Hill BT, Price LA.Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate[J]. Am J Clin Oncol, 1994, 17(1): 1-5.
[5] Hill BT, Price LA, MacRae K. Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous-cell carcinomas of the head and neck treated with initial combination chemotherapy without cisplatin[J]. J Clin Oncol, 1986, 4(9): 1340-1347.
[6] Abdel-Wahab M, Abitbol A, Lewin A, et al.Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma[J]. Am J Clin Oncol, 2005, 28(4): 359-366.
[7] Chaukar D, Prabash K, Rane P, et al.Prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery with neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer[J]. J Clin Oncol, 2022, 40(3): 272-281.
[8] Wang KX, Cui TY, Yang XD, et al.Study on efficacy and safety of low-dose apatinib combined with camrelizumab and SOX regimen as first-line treatment of locally advanced and unresectable gastric/gastroesophageal junction cancer: a protocol for an open-label, dose escalation and extension phase Ib clinical trial?[J].Onco Targets Ther, 2021, 14: 4859-4865.
[9] Yang G, Su X, Yang H, et al.Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma[J]. Ann Transl Med, 2021, 9(15): 1254-1265.
[10] Qiao ZY, Zhang ZJ, Lv ZC, et al.Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review[J]. Front Immunol, 2021, 12: 653437.
[11] Scott LJ.Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7): 747-758.
[12] Liao J, Jin H, Li S, et al.Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 454-462.
[13] Jia X, Wen Z, Sun Q, et al.Apatinib suppresses the proliferation and apoptosis of gastric cancer cells via the PI3K/Akt signaling pathway[J]. J BUON, 2019, 24(5): 1985-1991.
[14] Li J, Qin S, Xu J, et al.Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13): 1448-1454.
[15] Geng R, Song L, Li J, et al.The safety of apatinib for the treatment of gastric cancer[J]. Expert Opin Drug Saf, 2018, 17(11): 1145-1150.
[16] Zhao S, Ren S, Jiang T, et al.Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer[J]. Cancer Immunol Res, 2019, 7(4): 630-643.
[17] Xu J, Zhang Y, Jia R, et al.Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523.
[18] Lan C, Shen J, Wang Y, et al.Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2020, 38(34): 4095-4106.
[19] 赵灵颖, 张文青, 李存玺, 等. 阿帕替尼抗肿瘤作用机制研究进展[J]. 肿瘤防治研究, 2021, 48(1): 7-11.
Zhao LY, Zhang WQ, Li CX, et al.Research progress on antitumor mechanism of apatinib[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 7-11.
[20] 罗详冲, 李高峰. PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展[J]. 解放军医学杂志, 2020, 45(6): 672-679.
Luo XC, Li GF.Application of PD-1 inhibitor camrelizumab in advanced malignancies[J]. Medical Journal of Chinese People's Liberation Army, 2020, 45(6): 672-679.
[21] Cai X, Wei B, Li L, et al.Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression[J]. Int Immunopharmacol, 2020, 88: 106858.
[22] Gebbia V, Mantovani G, Farris A, et al.Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase Ⅱ multicenter study[J]. Cancer, 1997, 79(7): 1394-1400.

局部晚期口腔鳞癌新辅助免疫靶向治疗2例及文献复习

Neoadjuvant immunotarget therapy in patients with locally advanced oral squamous cell carcinoma: report of 2 cases and literature review

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘恒, 段晓峰. 铁自噬及相关基因NCOA4、FTH1在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(1): 87-91.
[2]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[3]	许刚, 宋其义, 蒋卫东, 刘景秀. 水通道蛋白3在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 478-482.
[4]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.
[5]	魏东亮, 李智, 鞠侯雨, 吴云腾, 郭伟, 任国欣. EGFR靶向药物对口腔癌疼痛缓解作用的机制探讨[J]. 中国口腔颌面外科杂志, 2022, 20(3): 219-224.
[6]	孙大为, 张云, 朱勇. shRNA干扰Rce1基因表达对口腔鳞癌细胞放射敏感性的影响[J]. 中国口腔颌面外科杂志, 2022, 20(2): 123-128.
[7]	努尔曼古丽·牙森, 多力昆·吾甫尔, 白尔娜·吾守尔, 闫广鹏. 血清IL-6、IL-17、TNF-α和IFN-γ水平与60例口腔鳞癌患者临床特征关系探讨[J]. 中国口腔颌面外科杂志, 2022, 20(2): 141-145.
[8]	瞿楚翔, 孙树洋, 张志愿. 从遗传异质性认识口腔鳞癌的侵袭过程[J]. 中国口腔颌面外科杂志, 2022, 20(2): 193-197.
[9]	王育新, 王志勇, 王永功, 王慧明, 王丽珍, 田皞, 叶金海, 付坤, 阮敏, 孙长伏, 孙国文, 刘法昱, 许碧云, 后军, 刘冰, 刘亮, 陈永锋, 陈占伟, 肖灿, 李思毅, 李志勇, 李勇, 李楠, 张陈平, 张东升, 张胜, 张凯, 杨溪, 何巍, 苏彤, 季彤, 林李嵩, 罗瑞华, 赵志立, 胡勤刚, 唐瞻贵, 徐蔚嘉, 黄志权, 黄晓峰, 梁玉洁, 韩正学, 韩伟, 蒋灿华, 喻建军, 蔡志刚, 廖贵清, 廖圣恺, 蔡惠明, 魏建华. 吲哚菁绿荧光成像技术在口腔鳞癌治疗中的应用：中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(1): 1-6.
[10]	李行, 许飞虎, 杨云博, 韩楠男, 阮敏. 口腔鳞癌腮腺淋巴结转移的临床病理特征与预后分析[J]. 中国口腔颌面外科杂志, 2022, 20(1): 28-31.
[11]	杨云博, 王钰璞, 李行, 韩楠男, 严明, 阮敏. 半胱氨酸酶抑制剂A在口腔鳞癌中的表达及临床意义[J]. 中国口腔颌面外科杂志, 2021, 19(6): 494-499.
[12]	黄金云, 张心怡, 鞠侯雨, 冀洪海, 任国欣. 口腔微生物稳态与口腔鳞癌患者顺铂敏感性的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(6): 500-505.
[13]	黄金云, 张心怡, 鞠侯雨, 冀洪海, 任国欣. 口腔微生物稳态与口腔鳞癌患者顺铂敏感性的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(6): 506-510.
[14]	李曼容, 娄雅静. Orem自理模式在90例口腔鳞癌患者游离组织瓣移植术后的应用价值评价[J]. 中国口腔颌面外科杂志, 2021, 19(6): 553-556.
[15]	杨玥怡, 张益益, 李一新, 琚梧桐, 钟来平. 多学科协作诊疗模式在口腔鳞癌中的实践进展[J]. 中国口腔颌面外科杂志, 2021, 19(5): 474-477.